Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA
CEO John Lepore, who was previously head of research at GSK, describes how the company is screening all proteins that are made by ribosomes, and then tests the functionality of novel ones to see if they can be harnessed as therapeutics or new drug targets.